Long-term safety follow-up for eplontersen in ATTR heart disease
Part of Hormones & metabolism clinical trials.
This is a long-term study to check the safety of eplontersen over time in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). It is mainly for people who already took the study medication before, or who joined an earlier related study and are doing well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You finished the earlier main study (or were in a related earlier study for ATTR-CM) and did well in it
- Your doctor is willing to restart you on eplontersen in an open-label (no-unknowns) way
- You can take vitamin A as instructed in the study plan
- You did not permanently stop the study drug during the earlier main/related studies
- No new health problem or worsening condition is making you unsuitable or interfering with the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment, NTLA-2001, for people with a type of heart disease called transthyretin amyloidosis with cardiomyopathy. It aims to see if the medicine can help improve heart function and quality of life.
This study observes people with ATTR-CM (a heart condition caused by a protein called transthyretin) who are starting treatment with vutrisiran or another approved therapy. It aims to understand how the disease progresses and how treatments work in real life.
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
This study follows people who already took part in an earlier trial (D8450R00003) to see how safe eplontersen is over the long term. It also includes people who had a liver transplant or severe liver problems.
This study tracks the safety of eplontersen during pregnancy and breastfeeding by collecting reports from people who have taken it. It helps doctors understand any risks to the baby or mother.
This study evaluates the long-term safety and effectiveness of the study drug ALXN2220 in people with transthyretin amyloid cardiomyopathy. It is an extension of a previous trial, so if you completed the earlier study, you may be able to continue receiving the treatment and be monitored for a longer period.
Hear when a new Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.